Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on July 25, 2016. The report discloses a material event regarding the company's independent registered public accounting firm for the fiscal year ending December 31, 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in corporate governance regarding the external auditor.
Material Changes
- Change in Certifying Accountant: On July 25, 2016, the Company engaged Baker Tilly Virchow Krause, LLP ("Baker Tilly") as its new independent registered public accounting firm.
- Consultation History: The Company confirmed it did not consult with Baker Tilly during the fiscal years ended December 31, 2015 and 2014, or during the interim period through July 24, 2016, regarding accounting principles, audit opinions, or reportable events.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of the auditor change.
Investor Verification Checklist
- Verify the identity and credentials of the new auditor, Baker Tilly Virchow Krause, LLP.
- Review the Company's subsequent filings (e.g., 10-K or 10-Q) to determine if the previous auditor's departure was due to any disagreements or reportable events not detailed in this 8-K.
- Confirm the effective date of the engagement for the fiscal year ending December 31, 2016.